Cardiac computed tomography-derived myocardial tissue characterization after anthracycline treatment.
Sign Up to like & getrecommendations! Published in 2022 at "ESC heart failure"
DOI: 10.1002/ehf2.13867
Abstract: AIMS Understanding cardiac function after anthracycline administration is very important from the perspective of preventing the onset of heart failure. Although cardiac magnetic resonance and echocardiography are recognized as the 'gold standard' for detecting cardiotoxicity,… read more here.
Keywords: computed tomography; tissue; anthracycline treatment; cardiac computed ... See more keywords
Early myocardial oedema can predict subsequent cardiomyopathy in high‐dose anthracycline therapy
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14232
Abstract: This study aims to assess subclinical changes in functional and morphologic myocardial MR parameters very early into a repetitive high‐dose anthracycline treatment (planned cumulative dose >650 mg/m2), which may predict subsequent development of anthracycline‐induced cardiomyopathy… read more here.
Keywords: predict subsequent; anthracycline; early myocardial; myocardial oedema ... See more keywords
Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review
Sign Up to like & getrecommendations! Published in 2018 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-018-0547-8
Abstract: Opinion statementAnthracycline-based regimens have been an important treatment component for patients with breast cancer. As demonstrated in the last Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, anthracycline-based regimens decrease breast cancer mortality by 20–30%.… read more here.
Keywords: risk; anthracycline; breast cancer; cancer ... See more keywords
Use of speckle tracking echocardiography to detect late anthracycline-induced cardiotoxicity in childhood cancer: A prospective controlled cross-sectional study.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2022.02.012
Abstract: BACKGROUND This study aimed to detect late sub-clinical patterns of cardiac dysfunction using speckle tracking echocardiography (STE) in children with cancer remission more than 12 months after the end of anthracycline treatment. METHODS This prospective controlled… read more here.
Keywords: cancer; study; echocardiography; detect late ... See more keywords
Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma
Sign Up to like & getrecommendations! Published in 2017 at "Cardiology in the Young"
DOI: 10.1017/s1047951117001536
Abstract: Abstract Objectives Anthracycline cardiotoxicity is an important side-effect in long-term childhood cancer survivors. We evaluated the incidence of and factors associated with anthracycline cardiotoxicity in a population of patients diagnosed with bone or soft tissue… read more here.
Keywords: sarcoma; tissue sarcoma; soft tissue; anthracycline ... See more keywords
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0557-8
Abstract: Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOEP (CHOP + etoposide), represent the current standard of care for patients with newly diagnosed peripheral T-cell lymphomas (PTCLs), although responses are unsatisfactory. In this study, we… read more here.
Keywords: choep; cell; anthracycline; chop ... See more keywords
Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes
Sign Up to like & getrecommendations! Published in 2019 at "Current Opinion in Cardiology"
DOI: 10.1097/hco.0000000000000617
Abstract: Purpose of review Advances in cancer treatments have resulted in significant improvements in survival. Anthracycline chemotherapeutics play a major role in the treatment of hematologic malignancies and solid tumors; however, there is a risk of… read more here.
Keywords: prognosis outcomes; anthracycline; recommendations prognosis; anthracycline cardiomyopathy ... See more keywords
Heart of the matter: reverse takotsubo syndrome in an anthracycline-exposed oncology patient
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2018-226378
Abstract: A 24-year-old man with acute myelogenous leukaemia and a history of anthracycline treatment is hospitalised for non-anthracycline chemotherapy. He develops new-onset heart failure requiring intesive care unit (ICU) admission during his stay. There is debate… read more here.
Keywords: reverse takotsubo; anthracycline; takotsubo syndrome; heart matter ... See more keywords
Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity
Sign Up to like & getrecommendations! Published in 2022 at "Oxidative Medicine and Cellular Longevity"
DOI: 10.1155/2022/5818612
Abstract: Anthracyclines are chemotherapeutic agents widely used to treat a variety of cancers, and these drugs have revolutionized our management of cancer patients. The dose-dependent cardiotoxicity of anthracyclines, however, remains one of the leading causes of… read more here.
Keywords: anthracycline; underlying pathogenesis; genetic susceptibility; cardiotoxicity ... See more keywords
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-3646
Abstract: Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase… read more here.
Keywords: anthracycline; arm; carboplatin; cancer ... See more keywords
High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Clinical Biochemistry"
DOI: 10.1177/0004563216650464
Abstract: Background Anthracycline drugs are effective anticancer agents, but their optimal use is limited in many patients by the associated cardiotoxicity, even at designated safe doses. As conventionally sensitive cardiac troponin-I assays fail to reliably quantify… read more here.
Keywords: high sensitive; anthracycline; cardiac troponin; sensitive cardiac ... See more keywords